|09/07/17||vTv Therapeutics Presents Further Dose Response Analysis from Phase 2 Study of its GLP-1 Receptor Agonist at 53rd Annual Meeting of the European Association for the Study of Diabetes|
|HIGH POINT, N.C.--(BUSINESS WIRE)--Sep. 7, 2017--
vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that
additional analysis from a Phase 2 clinical study of TTP273, an
investigational, oral small molecule GLP-1 receptor (GLP-1R) agonist for
the treatment of type 2 diabetes will be presented at the 53rd Annual
Meeting of the European Association for the Study of Diabetes (EASD)
held in Lisbon, Portugal, September 11 – 15, 2017.
|09/06/17||JDRF and vTv Therapeutics Announce Collaboration on Phase 2 Study of Novel Treatment for Type 1 Diabetes|
|vTv Therapeutics and JDRF enter into a $6 million industry
partnership to explore the effect of liver-selective glucokinase
activator TTP399 as an insulin-adjunctive therapy in type 1 diabetes
HIGH POINT, N.C.--(BUSINESS WIRE)--Sep. 6, 2017--
vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that JDRF, the
leading global organization funding type 1 diabetes (T1D) research, will
provide funding to support a Phase 2 Proof of Concept study to explore... |
|08/03/17||vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using Azeliragon|
|HIGH POINT, N.C.--(BUSINESS WIRE)--Aug. 3, 2017--
vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S.
Patent and Trademark Office has issued a patent with claims protecting
methods of treatment using azeliragon, the Company’s oral antagonist of
the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of
mild Alzheimer’s disease. The patent number is 9,717,710 (‘710 Patent).
The ‘710 Patent, expiring in October 2034, inc... |
|08/02/17||vTv Therapeutics Reports Second Quarter 2017 Financial and Operational Results|
|HIGH POINT, N.C.--(BUSINESS WIRE)--Aug. 2, 2017--
vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today provided a corporate
update and reported financial and operational results for the second
quarter ended June 30, 2017.
“With positive progress in our lead Alzheimer’s and diabetes programs,
vTv is pleased to showcase another productive quarter,” said Steve
Holcombe, president and CEO of vTv Therapeutics. “At the American
Diabetes Association ... |